15
July 2024
Hellenic Dynamics
plc
("Hellenic Dynamics" or the
"Company")
Settlement of Fees and Issue
of Equity
London, 15 July 2024: Further
to the Company's announcement dated 26 October 2023,
Hellenic Dynamics Plc (LSE: HELD), a medical
cannabis cultivator with a dedicated focus on producing
tetrahydrocannabinol ("THC") dominant strains of medical cannabis
flowers for the fast growing global medical cannabis
markets, announces that RiverFort Global
Opportunities PCC Ltd ("Riverfort") has elected to subscribe for
ordinary shares of 0.1 pence each in Hellenic Dynamics ("Ordinary
Shares") in order to discharge part of an outstanding loan and
accrued interest, which was issued pursuant to the mezzanine loan
announced 26 October 2023, and to settle a legal fee.
The loan and accrued interest of
£39,600 will be settled via the issue of 4,000,000 new Ordinary
Shares, based on the terms of the agreement between Hellenic and
Riverfort and the legal fee of £3,600 will be settled via the issue
of 363,636 new Ordinary Shares on the same terms (together the "New
Ordinary Shares"). Noting the announcement made on 16 May 2024, any
further payments due to RiverFort, pursuant to the amended
mezzanine loan agreement, will be deferred until the earlier of 30
September 2024, or receipt of the long term loan announced on 22
April 2024, now expected to be received in July 2024.
Admission and Total Voting Rights
Applications have been made to the
Financial Conduct Authority ("FCA") and the London Stock Exchange
Group Plc ("LSE") for the admission to the Official List of the FCA
and to trading on the Main Market of the LSE respectively, of the
4,363,636 New Ordinary Shares in respect of the settlement. It is
expected that the New Ordinary Shares will be admitted to trading
and dealings will commence on the LSE on or around 16 July 2024
("Admission"). The New Ordinary Shares will rank pari passu in all
respects with the Company's existing ordinary shares of 0.1 pence
each, currently traded on the Main Market of the London Stock
Exchange.
Following Admission, the Company's
issued share capital will comprise 146,907,454 ordinary shares of
0.1 pence each. The figure 146,907,454 will represent the total
voting rights in the Company and may be used by shareholders as the
denominator for the calculation by which they can determine if they
are required to notify their interest in, or a change to their
interest in, the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.
This announcement contains inside information for the purposes
of article 7 of the Market Abuse Regulation (EU) 596/2014 as
amended by regulation 11 of the Market Abuse (Amendment) (EU Exit)
Regulations 2019/310. With the publication of this announcement,
this information is now considered to be in the public
domain.
The
Directors of the Company take responsibility for this
announcement.
Enquires:
Hellenic Dynamics plc
|
+44 (0)20 3818 7850
|
Davinder Rai
|
davinder@hellenicdynamics.com
|
|
|
Cairn Financial Advisers LLP
|
+44 (0)20 7213 0880
|
Emily Staples / Jo Turner
|
|
|
|
Peterhouse Capital
|
+44 (0)20 7469 0930
|
Lucy Williams / Charles
Goodfellow
|
|
About Hellenic Dynamics plc
Founded in 2019, Hellenic Dynamics is specifically focused on
the cultivation and supply of THC ("tetrahy-drocannabinol") -
dominant strains of medical cannabis flowers, destined for the
growing global medical can-nabis markets. Hellenic Dynamics' core
strategy is to develop and operate its 40,000 square metre active
culti-vation licence from its 195,506 square metre facility located
near Thessaloniki in Northern Greece. In full production, Hellenic
Dynamics is capable of producing over 54,000 kg of dried flowers
per annum.
Hellenic Dynamics will take
advantage of its relatively low cost base resulting from a
comparatively low cost of power, having its own running water
supply and the labour rates for skilled and semi-skilled labour in
Northern Greece.
29 European countries now allow
medical cannabis via prescription and the European cannabis market
is ex-pected to reach $7.25 billion per annum by 2029. Sales of
Hellenic Dynamics' dried THC-dominant cannabis flowers and extracts
are initially intended for export into Europe, in addition to other
international markets and domestically in Greece.
As the first medical cannabis
cultivator to obtain a listing on the main market for listed
securities of the Lon-don Stock Exchange, Hellenic Dynamics is
significantly different to the number of CBD (Cannabidiol) related
companies that have appeared over the recent years. Hellenic
Dynamics cultivates THC-dominant medical cannabis flowers.
THC-dominant medical cannabis products are only available via a
medical prescription. Medicinal cannabis has been approved for use
both in the United Kingdom and Germany, plus 24 other Euro-pean
countries, for conditions including but not limited to chronic
pain, intractable chemotherapy-related nau-sea, anxiety, insomnia,
Tourette's syndrome, substance use disorder, multiple sclerosis,
IBS, spinal cord treat-ment, lack of appetite due to HIV/AIDS,
cachexia, anorexia and glaucoma.
For further information please visit
our website www.hellenicdynamics.com
Caution regarding forward looking statements
Certain statements in this
announcement, are, or may be deemed to be, forward looking
statements. Forward looking statements are identified by their use
of terms and phrases such as ''believe'', ''could'', "should"
''envis-age'', ''estimate'', ''intend'', ''may'', ''plan'',
''potentially'', "expect", ''will'' or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements reflect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.